|Title||PharmAbcine to Participate in BIO Digital Conference|
PharmAbcine to Participate in BIO Digital Conference
Published: May 27, 2020
Daejeon, Korea, May 26, 2020 - PharmAbcine Inc. (KOSDAQ: 208340) announced today that the company will be participating in BIO(Biotechnology Innovation Organization) Digital Conference over June 8-12. The BIO International Convention is holding its annual event virtually this year amidst the COVID-19 global pandemic. The event brings together capital, scientific and development expertise needed to turn promising innovation into successful medicine.
During the digital gathering, PharmAbcine, a therapeutic antibody development company, will be holding virtual meetings with potential global partners to share information on its pre-clinical and clinical assets. Virtual meeting times are still available to those participating.
“By participating in BIO Digital, the company aims to introduce its front runner product, olinvacimab, an angiogenesis regulator, and the two new additions to its pipeline,” says Dr. Jin-San Yoo, CEO of PharmAbcine. “The two new additions include 1) PMC-402, a TIE-2 activating blood vessel stabilizer and 2) PMC-309, an anti-VISTA immune checkpoint inhibitor.”
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, respiratory, to renal pathology.
PharmAbcine’s leading pipeline, olinvacimab, an anti-VEGFR2 neutralizing fully human IgG, is currently in a phase II study for Bevacizumab nonresponding rGBM (recurrent glioblastoma multiforme) patients in both US and Australia. In collaboration with MERCK,
olinvacimab plus pembrolizumab Phase Ib trials for mTNBC and rGBM are on-going.
PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine’s advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With its highly advanced technology platforms, it provides high-quality
antibody generation services. The high standards have allowed PharmAbcine to expand co-development opportunities with not only existing but also potential partners.
Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com
About the BIO International Convention:
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners, educational resources, and the insights for attendees to continue critical research and development.
For more information visit https://www.bio.org/events/bio-digital
please visit the website at